Free Trial
NASDAQ:SUPN

Supernus Pharmaceuticals (SUPN) Stock Price, News & Analysis

Supernus Pharmaceuticals logo
$50.17 +0.41 (+0.82%)
Closing price 10/17/2025 04:00 PM Eastern
Extended Trading
$50.83 +0.66 (+1.31%)
As of 10/17/2025 05:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Supernus Pharmaceuticals Stock (NASDAQ:SUPN)

Advanced

Key Stats

Today's Range
$49.44
$50.85
50-Day Range
$40.57
$50.17
52-Week Range
$29.16
$51.78
Volume
630,165 shs
Average Volume
749,122 shs
Market Capitalization
$2.81 billion
P/E Ratio
43.63
Dividend Yield
N/A
Price Target
$64.00
Consensus Rating
Buy

Company Overview

Supernus Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
81st Percentile Overall Score

SUPN MarketRank™: 

Supernus Pharmaceuticals scored higher than 81% of companies evaluated by MarketBeat, and ranked 190th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Supernus Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.

  • Upside Potential

    Supernus Pharmaceuticals has a consensus price target of $64.00, representing about 27.6% upside from its current price of $50.17.

  • Amount of Analyst Coverage

    Supernus Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.

  • Read more about Supernus Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Supernus Pharmaceuticals are expected to decrease by -39.50% in the coming year, from $2.38 to $1.44 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Supernus Pharmaceuticals is 43.63, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 225.15.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Supernus Pharmaceuticals is 43.63, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 85.62.

  • Price to Book Value per Share Ratio

    Supernus Pharmaceuticals has a P/B Ratio of 2.67. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Supernus Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    9.83% of the float of Supernus Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Supernus Pharmaceuticals has a short interest ratio ("days to cover") of 6.3.
  • Change versus previous month

    Short interest in Supernus Pharmaceuticals has recently increased by 3.39%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Supernus Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Supernus Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    9.83% of the float of Supernus Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Supernus Pharmaceuticals has a short interest ratio ("days to cover") of 6.3.
  • Change versus previous month

    Short interest in Supernus Pharmaceuticals has recently increased by 3.39%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Supernus Pharmaceuticals has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Supernus Pharmaceuticals this week, compared to 8 articles on an average week.
  • Search Interest

    11 people have searched for SUPN on MarketBeat in the last 30 days. This is an increase of 1,000% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Supernus Pharmaceuticals to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Supernus Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $16,390,592.00 in company stock.

  • Percentage Held by Insiders

    Only 8.80% of the stock of Supernus Pharmaceuticals is held by insiders.

  • Read more about Supernus Pharmaceuticals' insider trading history.
Receive SUPN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Supernus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

SUPN Stock News Headlines

Buy alert: Move $1,000 before Tesla’s Optimus launch
Elon's $1,000,000,000,000 payday Elon Musk just made his biggest insider purchase of Tesla stock ever. He's preparing for a "mind blowing" new launch that could see Tesla move away from electric cars... and into a new market.tc pixel
See More Headlines

SUPN Stock Analysis - Frequently Asked Questions

Supernus Pharmaceuticals' stock was trading at $36.16 at the start of the year. Since then, SUPN stock has increased by 38.7% and is now trading at $50.17.

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) issued its quarterly earnings data on Tuesday, May, 6th. The specialty pharmaceutical company reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.26 by $0.02. The company's quarterly revenue was up 4.3% on a year-over-year basis.
Read the conference call transcript
.

Top institutional investors of Supernus Pharmaceuticals include Rice Hall James & Associates LLC (0.85%), Pacer Advisors Inc. (0.34%), Wedge Capital Management L L P NC (0.12%) and Voya Investment Management LLC (0.08%). Insiders that own company stock include Jack A Khattar, Tami Tillotson Martin, Frederick M Hudson, Frank Mottola, Georges Gemayel, Padmanabh P Bhatt, Jonathan Rubin, Timothy C Dec and Bethany Sensenig.
View institutional ownership trends
.

Shares of SUPN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Supernus Pharmaceuticals investors own include American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), DiamondRock Hospitality (DRH), The RMR Group (RMR), Humana (HUM) and AUO (AUOTY).

Company Calendar

Last Earnings
5/06/2025
Today
10/18/2025
Next Earnings (Estimated)
11/03/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - GENERIC DRG
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:SUPN
CIK
1356576
Employees
580
Year Founded
2005

Price Target and Rating

High Price Target
$65.00
Low Price Target
$63.00
Potential Upside/Downside
+27.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
$1.15
Trailing P/E Ratio
43.63
Forward P/E Ratio
21.08
P/E Growth
N/A
Net Income
$73.86 million
Net Margins
9.70%
Pretax Margin
12.35%
Return on Equity
14.22%
Return on Assets
10.82%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.58
Quick Ratio
2.43

Sales & Book Value

Annual Sales
$661.82 million
Price / Sales
4.25
Cash Flow
$4.21 per share
Price / Cash Flow
11.93
Book Value
$18.76 per share
Price / Book
2.67

Miscellaneous

Outstanding Shares
56,070,000
Free Float
51,139,000
Market Cap
$2.81 billion
Optionable
Optionable
Beta
0.78

Social Links

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:SUPN) was last updated on 10/18/2025 by MarketBeat.com Staff
From Our Partners